MUCL1

MUCL1 (SBEM) is a glycoprotein that acts as an oncogenic effector across multiple cancers and in endothelial inflammation, driving proliferation, EMT, invasion, and chemoresistance through β-catenin- and NF-κB-linked signaling (PMID:35059735, PMID:41770679). In colorectal cancer cells, MUCL1 promotes β-catenin activation via Ser-552 phosphorylation and nuclear accumulation, sustaining EMT and the anti-apoptotic effectors Bcl2/BclxL, such that its silencing restores E-cadherin and reduces invasion and migration (PMID:35059735). In breast cancer, MUCL1 interacts with the phosphatase DUSP16 and activates AMPK signaling to confer paclitaxel resistance, with knockdown increasing apoptosis and restoring drug sensitivity (PMID:41181635). MUCL1 protein stability is controlled post-translationally by two distinct modifications: ST3GAL1 directly binds and sialylates MUCL1 to increase its stability and promote tumor growth and lung metastasis (PMID:41770470), while UCHL1 stabilizes MUCL1 through deubiquitination, and this UCHL1–MUCL1 axis drives LPS-induced endothelial inflammation and apoptosis in HUVECs via the β-catenin/NF-κB pathway (PMID:41770679). Its expression is post-transcriptionally suppressed by miR-186-5p, whose overexpression dampens PI3K/AKT signaling and downstream matrix metalloproteinases and cell-cycle effectors (PMID:37477531). Beyond these signaling and stability axes, the biochemical activity of the MUCL1 glycoprotein itself has not been characterized in the available corpus.

1. 2021 Low

   Established an early functional association by linking MUCL1 expression inversely to melanogenesis and metastatic gene activity, hinting at a context-dependent regulatory role beyond secretory mucin biology.

   Evidence microarray expression analysis and threonine-treatment validation in melanocytes and melanoma cells

   PMID:34545566

   Open questions at the time

   • Correlative and expression-based with limited mechanistic validation
   • FOXO/autophagy placement inferred, not directly tested
   • No direct molecular activity for MUCL1 defined
2. 2022 Medium

   Answered how MUCL1 promotes malignant phenotype by placing it upstream of β-catenin, showing it drives Ser-552 phosphorylation and nuclear accumulation to sustain EMT and anti-apoptotic transcription.

   Evidence siRNA knockdown, Western blotting, invasion/migration assays in HT-29 and SW620 colorectal cancer cells

   PMID:35059735

   Open questions at the time

   • Mechanism by which MUCL1 induces β-catenin Ser-552 phosphorylation not defined
   • No direct binding partner identified for the β-catenin axis
   • Single tumor type
3. 2023 Medium

   Identified an upstream regulator of MUCL1, showing miR-186-5p suppresses MUCL1 and dampens PI3K/AKT-driven proliferation and invasion programs.

   Evidence miR-186-5p mimic/inhibitor transfection with PI3K activator (740Y-P) rescue, migration/invasion/proliferation assays in MDA-MB-231 cells

   PMID:37477531

   Open questions at the time

   • Direct 3'UTR targeting not confirmed by luciferase reporter in abstract
   • How MUCL1 connects to PI3K/AKT activation mechanistically unresolved
4. 2025 Medium

   Defined a chemoresistance mechanism by linking MUCL1 to DUSP16 interaction and AMPK activation, explaining paclitaxel resistance in breast cancer.

   Evidence SBEM overexpression/knockdown, AMPK activator rescue, apoptosis assays in drug-resistant breast cancer cells

   PMID:41181635

   Open questions at the time

   • DUSP16 interaction lacks reciprocal Co-IP confirmation
   • How MUCL1 activates AMPK not mechanistically resolved
   • Link between DUSP16 and AMPK not established
5. 2026 High

   Resolved two converging mechanisms of MUCL1 protein stability control—deubiquitination by UCHL1 and sialylation by ST3GAL1—and connected these to endothelial inflammation and tumor metastasis respectively.

   Evidence Co-IP, ubiquitination and CHX-chase assays in HUVECs (UCHL1) and direct binding/sialylation assays plus xenograft and metastasis models (ST3GAL1)

   PMID:41770470 PMID:41770679

   Open questions at the time

   • The MUCL1 ubiquitination sites and E3 ligase remain unidentified
   • Sialylation sites on MUCL1 not mapped
   • Whether sialylation and deubiquitination act on the same MUCL1 pool is untested

• The intrinsic biochemical activity of the MUCL1 glycoprotein and how it physically couples to β-catenin, NF-κB, and AMPK signaling remain undefined.
• No molecular function assigned to MUCL1 itself
• No structural model or receptor/effector binding mechanism
• Subcellular localization of active MUCL1 not established